Pfizer 10Q 2010 Q1 Quarterly report | PFE Filing

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: adjuvant, affordable, AI, al, Alaska, alfa, Alphapharm, altogether, Amgen, amyloid, ankylosing, ann, antibiotic, antidepressant, arm, attendant, atypical, autism, bapineuzumab, bazedoxifene, BeneFIX, biomarker, biosimilar, bleeding, bring, calcium, called, candidate, Capsugel, Centersource, Centre, certiorari, chemical, chewable, childhood, claimant, comp, con, CONBRIZA, CONCERT, conjugate, CONSTELLATION, constitute, contracture, convene, cord, corroborated, counterparty, criteria, curtailment, damage, deliverable, demand, device, Diet, dietary, disc, disciplined, dispensed, disposable, distinct, dition, divestiture, dosing, doughnut, Dupuytren, Effexor, Electrical, Enbrel, endothelial, escrow, estrogen, examination, exclusivit, fact, family, feared, Florida, foregoing, fracture, Gaucher, GmbH, Guide, heard, hemophilia, hemorrhoidal, hepatic, hepatocellular, hepatotoxicity, hole, Horizon, Huntingdon, Immunotherapy, incidence, incre, infant, inflation, inp, insert, intervening, invasive, Israel, Janssen, Johnson, juvenile, Kingdom, latrepiridine, LDL, length, leukemia, lifelong, Likewise, lithium, LLC, lose, macroeconomic, master, matching, MDL, menopausal, menopause, Minnesota, mission, mitigation, MMR, moderate, modest, molecule, multidose, National, ne, neuroendocrine, neurological, North, Nycomed, orphan, ou, outpatient, panic, partly, pathway, personal, petition, plaque, pneumococcal, Pondimin, Premarin, preservative, prima, Pristiq, Proceeding, prominently, Protalix, Protonix, provisional, psoriatic, Pty, qualification, Ranbaxy, randomized, Rapamune, Redux, ReFacto, rejected, reliable, remanded, retiree, retrospectively, rily, ris, robable, rubella, secondary, sector, shortly, social, sorafenib, spinal, spine, sponsored, src, stayed, stipulation, stream, strive, subsidy, Sun, supplier, taliglucerase, theory, thimerosal, thousand, tissue, toddler, tumor, type, tyrosine, ual, uncommonly, underway, unemployment, ur, ussion, uts, vaccine, valproate, variation, vascular, vasomotor, VEGF, visual, Viviant, vulvar, warrant, Watson, win, XR, Xyntha, young

Removed: aaa, absence, accountability, accounted, accumulated, acquire, acquirer, actively, adapt, add, addressing, advantage, Africa, Agile, agitation, allergy, amortized, announcement, anticipation, applied, approximating, arising, assign, assigned, asthma, authorization, autoimmune, axitinib, base, behavior, breached, broadened, callable, capecitabine, capitalization, capitalize, captured, ceased, centralized, Champix, characterize, chart, choice, clear, Coley, collaborative, colorectal, Combivir, commercializing, commitment, community, compliance, complicated, compound, concurred, confident, conform, contracting, converted, convertible, counterbalance, County, couple, covering, create, customer, dalbavancin, decided, dedicated, deductible, defensive, defer, Department, deployment, deposit, depressed, depth, developer, developing, distributing, distributor, diverse, dopamine, downgraded, dramatic, East, effectively, efficiency, efficiently, effort, eliminating, enantiomer, essentially, execute, expanded, expanding, expensing, exploration, facing, fewer, fiduciary, fight, final, footage, forecasted, gelatin, generalized, generated, generating, genitourinary, GlaxoSmithKline, growing, GSK, hired, historical, HIV, hold, impaired, improved, improvement, India, initial, innovation, intercompany, invested, investee, investor, issuer, Kivexa, largest, lessee, leucovorin, LIBOR, licensing, liquidation, long, lump, maraviroc, marketed, marketplace, mechanism, met, method, Middle, milestone, Modernization, modestly, mood, movement, negotiation, network, Neurontin, neuropsychiatric, newly, obstructive, obtaining, occurring, offering, ophthalmology, opportunistic, opposite, organizational, originally, outlook, outsourced, packaging, parent, participate, partnership, PEARL, physician, plc, Postmenopausal, Pravachol, pravastatin, preclinical, preferential, prejudice, preliminary, preparing, prescribing, present, principle, privately, procurement, Productive, profoundly, progressed, promoting, promotion, prospectively, Protocol, psychotropic, punitive, purpose, quickly, rationalization, recession, reclassify, recurred, referenced, refunded, reinvest, relationship, renewal, Reorganization, resilience, respond, resulted, safe, security, serotonin, served, settle, ship, shortening, signal, simvastatin, Singapore, site, skin, smaller, spending, square, stop, streamline, streamlined, strength, succeed, suffering, suicidal, sum, suspected, sustain, swap, switch, Taiwan, tanezumab, targeted, tempered, temporary, Thailand, threat, title, Toronto, transformation, transforming, transplant, unsuccessful, utilizing, valuable, veterinary, Visit, weakened, Zocor

	Three Months Ended April 4,		Year Ended December 31,
(in millions, except ratios)	2010		2009		2008		2007		2006		2005

Determination of earnings:
Income from continuing operations
before provision for taxes on income, noncontrolling interests and cumulative effect of a change in accounting principles	$	3,179	$	10,827	$	9,694	$	9,278	$	13,028	$	10,800
Less:
Noncontrolling interests		9		9		23		42		12		12
Income attributable to Pfizer Inc.		3,170		10,818		9,671		9,236		13,016		10,788
Add:
Fixed charges		553		1,361		647		541		642		622
Total earnings as defined	$	3,723	$	12,179	$	10,318	$	9,777	$	13,658	$	11,410

Fixed charges:
Interest expense(a)	$	522	$	1,233	$	516	$	397	$	488	$	471
Preferred stock dividend(b)		1		7		8		11		14		14
Rents(c)		30		121		123		133		140		137
Fixed charges		553		1,361		647		541		642		622
Capitalized interest		9		34		46		43		29		17

Total fixed charges	$	562	$	1,395	$	693	$	584	$	671	$	639

Ratio of earnings to fixed charges		6.6		8.7		14.9		16.7		20.4		17.9

Pfizer (PFE) 10-Q2010 Q1 Quarterly report

Content analysis